About: Fevipiprant

Property	Value
dbo:abstract	Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2). As of 2016, it is in phase III clinical trials for the treatment of asthma. On Monday, December 16, 2019, Switzerland-based Novartis officially announced that it was jettisoning fevipiprant from its development program, given that the medicine has failed in two additional clinical trials in patients with moderate-to-severe asthma. The firm said that it had hoped fevipiprant would be a billion-dollar-selling asthma drug. (en) フェビピプラント（Fevipiprant）は、CRTH2受容体に対してアンタゴニストとなる化合物の1種である。ただし、2016年現在、医薬品としては実用化されていない。 (ja)
dbo:casNumber	872365-14-5
dbo:fdaUniiCode	2PEX5N7DQ4
dbo:kegg	D10631
dbo:pubchem	23582412
dbo:thumbnail	wiki-commons:Special:FilePath/Fevipiprant.svg?width=300
dbo:wikiPageID	51257095 (xsd:integer)
dbo:wikiPageLength	4517 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1033019669 (xsd:integer)
dbo:wikiPageWikiLink	dbc:Antiasthmatic_drugs dbc:Receptor_antagonists dbr:Pharmaceutical_drug dbr:Prostaglandin_DP2_receptor dbc:Carboxylic_acids dbc:Trifluoromethyl_compounds dbr:Clinical_trial dbr:Receptor_antagonist dbc:Benzosulfones dbr:Novartis dbr:Glucuronidation dbr:International_Nonproprietary_Name dbr:Asthma dbr:Phases_of_clinical_research dbr:Setipiprant
dbp:atcPrefix	none (en)
dbp:bioavailability	Unaffected by food (en)
dbp:c	19 (xsd:integer)
dbp:casNumber	872365 (xsd:integer)
dbp:chemspiderid	23582412 (xsd:integer)
dbp:eliminationHalfLife	72000.0
dbp:excretion	Renal (en)
dbp:f	3 (xsd:integer)
dbp:h	17 (xsd:integer)
dbp:iupacName	{2-methyl-1-[4--2-benzyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}acetic acid (en)
dbp:kegg	D10631 (en)
dbp:legalStatus	Investigational (en)
dbp:metabolism	Hepatic glucuronidation (en)
dbp:n	2 (xsd:integer)
dbp:o	4 (xsd:integer)
dbp:pubchem	23582412 (xsd:integer)
dbp:routesOfAdministration	Oral (en)
dbp:s	1 (xsd:integer)
dbp:smiles	CC1=CCCO (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	GFPPXZDRVCSVNR-UHFFFAOYSA-N (en)
dbp:unii	2 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Respiratory-system-drug-stub dbt:As_of dbt:Drugbox dbt:Prostanoidergics dbt:Reflist dbt:Asthma_and_copd_rx
dcterms:subject	dbc:Antiasthmatic_drugs dbc:Receptor_antagonists dbc:Carboxylic_acids dbc:Trifluoromethyl_compounds dbc:Benzosulfones
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	フェビピプラント（Fevipiprant）は、CRTH2受容体に対してアンタゴニストとなる化合物の1種である。ただし、2016年現在、医薬品としては実用化されていない。 (ja) Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2). As of 2016, it is in phase III clinical trials for the treatment of asthma. (en)
rdfs:label	Fevipiprant (en) フェビピプラント (ja)
owl:sameAs	yago-res:Fevipiprant wikidata:Fevipiprant dbpedia-ja:Fevipiprant https://global.dbpedia.org/id/2Xs5d
prov:wasDerivedFrom	wikipedia-en:Fevipiprant?oldid=1033019669&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Fevipiprant.svg
foaf:isPrimaryTopicOf	wikipedia-en:Fevipiprant
is dbo:wikiPageRedirects of	dbr:QAW039
is dbo:wikiPageWikiLink of	dbr:Prostaglandin_DP2_receptor dbr:Setipiprant dbr:QAW039
is foaf:primaryTopic of	wikipedia-en:Fevipiprant